Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Kirilys Therapeutics

Ownership
Private
Therapeutic Areas
Oncology
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small moleculesAntibody-drug conjugate (ADC)

Kirilys Therapeutics General Information

Kirilys has multiple precision oncology assets in development. Their lead compound KRLS-017 is a reversible small molecule inhibitor of CDK7 in preclinical stage, showing best-in-class potency, selectivity, and anti-tumor efficacy. KRLS-004 (ASN-004) is in Phase 1 for colorectal cancer and is an antibody-drug conjugate targeting 5T4-oncofetal glycoprotein.

Contact Information

Website
https://www.linkedin.com/company/kirilys
Primary Industry
Biotech
Corporate Office
San Francisco, California
United States

Drug Pipeline

KRLS-017
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Kirilys Therapeutics's pipeline data

Book a demo

Key Partnerships

D2G Oncology, Ube Industries

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Kirilys Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Kirilys Therapeutics's complete valuation and funding history, request access »

Kirilys Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals